PDL BioPharma (NASDAQ:PDLI) revises its Q2 revenue guidance to ~$122M, down from prior guidance of $128M, due to a mathematical error made on the earlier guidance. Shares -1.5%. (PR)
PDL BioPharma (NASDAQ:PDLI) revises its Q2 revenue guidance to ~$122M, down from prior guidance of $128M, due to a mathematical error made on the earlier guidance. Shares -1.5%. (PR)